2Lambert PA.Mechanisms of antibiotic resistance in Pseudomonas aeruginosa[J].J R Soc Med,2002,95(Supp141):22-26.
3Nikaido H.Prevention of drug access to bacterial targets:permea- bilty barriers and active efflux[J].Science,1994,264(5157):382-388.
4Yoshihara E,Nakae T.Identification of porins in the outer mem braneo I pesudomonas aeruginaosa that from small diffusion pores[J].J Biol Chern,1989,264(11):6297-6301.
5Kuo LC,Yu CJ,Lee LN,et al.Clinical features of parrdrug resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan[J].J Formos Med Assoc,2003,102(9):601-606.
6Yoneyama H,N akae T.Mrchanism of efficient elimination of protein D2[J].Antimicrob Agents Chemother,1993,37(11):2385- 2390.
7Bush K,Jacoby GA,MedeirosAA.A functionai classification scheme for β -Lactamases and aminoglycoside enzymes[J].Curr Opin Microbiol,1998,1 (5):509-515.
6Jafari NJ,Ranjbar R, Haghi-Ashtiani MT,et al. The study of prev- alence and antimicrobial susceptibility of tracheal bacterial strains isolated from pediatric patients [ J ]. Pak J Biol Sei, 2009, ! 2:455 - 458.
9Kumar E, Usha K, Ramana BV, et al, Prevalence of various β-lac- tamase (ESBL, AMPC AND MBL) producing multidrug resistant clinical isolates of Acinetobacter spp. in a tertiary care hospital [ J]. Asian J Pharmaceu Clinic Res,2013,6(4) :28.
10Bauvois C, Ibuka AS, Celso A, et al. Kinetic properties of four plasmid-mediated ampC β-lactamase [ J ]. Antimicrob Agents Chemother,2005,49(10 ) :4240.
